One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Social Isolation and Loneliness as Medical Issues
Julianne Holt-Lunstad, Ph.D., and Carla Perissinotto, M.D., M.H.S.
doi : 10.1056/NEJMp2208029
Vol. 388 No. 3
Medicare Overpayment for Outpatient Medication — A Supreme Court Ruling in Context
Wasan Kumar, B.S., and Kevin Schulman, M.D.
doi : 10.1056/NEJMp2212972
Better Off at Home — How We Fail Children with Complex Medical Conditions
Charles A. Newcomer, M.D.
doi : 10.1056/NEJMp2213657
Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture
Major Extremity Trauma Research Consortium (METRC)*
doi : 10.1056/NEJMoa2205973
Clinical guidelines recommend low-molecular-weight heparin for thromboprophylaxis in patients with fractures, but trials of its effectiveness as compared with aspirin are lacking.
Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years
Patricia Winokur, M.D., Juleen Gayed, M.B., B.S., David Fitz-Patrick, M.D., Stephen J. Thomas, M.D., Oyeniyi Diya, M.D., Stephen Lockhart, D.M., Xia Xu, Ph.D., Ying Zhang, Ph.D., Vishva Bangad, M.S., Howard I. Schwartz, M.D., Douglas Denham, D.O., Jose F. Cardona, M.D., J.D.,
doi : 10.1056/NEJMoa2213082
The emergence of immune-escape variants of severe acute respiratory syndrome coronavirus 2 warrants the use of sequence-adapted vaccines to provide protection against coronavirus disease 2019.
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma
Lipika Goyal, M.D., Funda Meric-Bernstam, M.D., Antoine Hollebecque, M.D., Juan W. Valle, M.D., Chigusa Morizane, M.D., Ph.D., Thomas B. Karasic, M.D., Thomas A. Abrams, M.D., Junji Furuse, M.D., Ph.D., Robin K. Kelley, M.D., Philippe A. Cassier, M.D., Heinz-Josef Klümpen, M.D., Ph.D., Heung-Moon Chang, M.D.,
doi : 10.1056/NEJMoa2206834
Alterations in fibroblast growth factor receptor 2 (FGFR2) have emerged as promising drug targets for intrahepatic cholangiocarcinoma, a rare cancer with a poor prognosis. Futibatinib, a next-generation, covalently binding FGFR1–4 inhibitor, has been shown to have both antitumor activity in patients with FGFR-altered tumors and strong preclinical activity against acquired resistance mutations associated with ATP-competitive FGFR inhibitors.
Psychosocial Functioning in Transgender Youth after 2 Years of Hormones
Diane Chen, Ph.D., Johnny Berona, Ph.D., Yee-Ming Chan, M.D., Ph.D., Diane Ehrensaft, Ph.D., Robert Garofalo, M.D., M.P.H., Marco A. Hidalgo, Ph.D., Stephen M. Rosenthal, M.D., Amy C. Tishelman, Ph.D., and Johanna Olson-Kennedy, M.D.
doi : 10.1056/NEJMoa2206297
Limited prospective outcome data exist regarding transgender and nonbinary youth receiving gender-affirming hormones (GAH; testosterone or estradiol).
Orbital Rhabdomyosarcoma
Erich J. Berg, D.O., and Jeremy D. Clark, M.D.
doi : 10.1056/NEJMicm2207328
Case 2-2023: A 76-Year-Old Man with Dizziness and Altered Mental Status
Antonio Granfone, M.D., Brooks P. Applewhite, M.D., Biff F. Palmer, M.D., and Soma Jobbagy, M.D., Ph.D.
doi : 10.1056/NEJMcpc2201240
Thromboprophylaxis after Extremity Fracture — Time for Aspirin?
Matthew Costa, Ph.D.
doi : 10.1056/NEJMe2214045
Growing Evidence and Remaining Questions in Adolescent Transgender Care
Annelou L.C. de Vries, M.D., Ph.D., and Sabine E. Hannema, M.D., Ph.D.
doi : 10.1056/NEJMe2216191
Audio Interview: Weighing the Protective Value of Covid-19 Infection
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., and Stephen Morrissey, Ph.D.
doi : 10.1056/NEJMe2300654
Disparities According to Genetic Ancestry in the Use of Precision Oncology Assays
doi : 10.1056/NEJMc2213457
Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo
doi : 10.1056/NEJMc2215181
